Navigation Links
Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
Date:3/13/2009

PRINCETON, N.J., March 13 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) announced today that it is expanding its clinical pharmacology footprint in Europe with the acquisition of Swiss Pharma Contract, a 50-bed clinical research company based in Basel, Switzerland.

"Our clients' need for complex, high-science clinical pharmacology studies that can help them make decisions faster is growing," said Joe Herring, Covance chief executive officer. "This acquisition significantly increases Covance's early clinical development footprint in Europe and gives our clients access to special patient populations for Phase I/IIa clinical studies. Covance's early clinical development offerings are well-positioned to provide our clients with the knowledge critical to enhancing downstream success rates."

Swiss Pharma Contract is an experienced, high-quality provider of clinical research services to the pharmaceutical, biotechnology, and medical-device industries, working with 10 of the top 20 pharmaceutical companies. Swiss Pharma Contract has conducted more than 200 complex clinical trials since 2002, with roughly a third of them being first-in-human studies. The Basel site also has substantial expertise in radiolabeled and proof-of-concept studies, a wealth of experience in specialty therapeutic areas, and access to a large and active volunteer database.

The business includes a modern, well-equipped clinical pharmacology facility that will increase Covance's global capacity to approximately 550 beds in the United States and Europe. The company's talented staff includes nine physicians as well as other medical staff experienced in complex clinical trials. All Swiss Pharma Contract employees will be offered employment at Covance.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest
'/>"/>

SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Covance Purchases Equity Stake in Caprion Proteomics
2. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
3. Covance Decides to Pursue Its Original Preclinical Strategy in China
4. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
5. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
6. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
8. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
9. Simbionix Increases Product Offerings for OB/GYN Physicians
10. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
11. Despite Economic Woes, Physician Compensation Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
(Date:5/16/2013)... Scientists at the Center for Learning and ... the California -based biopharmaceutical company Magceutics, ... for reversing memory decline in mice with Alzheimer,s Disease. ... improvement in advanced stage AD mice. The study is ... decline for advanced stage AD mice, and is also ...
(Date:5/16/2013)... 16, 2013 BioInformatics LLC New Market ... Stem Cell-Derived Cells: Current and Future Opportunities (13-004) ... suppliers in the primary cells market continues to increase. ... are used most often, how satisfied scientists are with ... and anticipated growth rate. ,  , Additionally, terminally ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... tea, soda and hot chocolate present risk, ... daily caffeine,during pregnancy -- whether from coffee, tea, ... risk of miscarriage, according a new study,by the ... for,the first time, pregnancy-related symptoms of nausea, vomiting ...
... antiviral activity in patients with ... NNRTI-resistant virus ... and Drug,Administration (FDA) has granted accelerated approval to the anti-HIV,medication ... to show antiviral activity in,treatment- experienced adult patients with HIV ...
... 18 Eli Lilly and Company,strongly objects to implications ... company has suppressed results of negative clinical,trials., The ... England Journal of,Medicine (NEJM), cited Prozac and Lilly as ... trial data. Not only was,the Times, story inaccurate when ...
Cached Biology Technology:Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 4FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 2FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 3FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 4FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 5FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 6FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 7FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 8In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 4
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2First Atlanta Science Festival set for 2014 2
... study led by Boston University School of Public Health ... decongestants during their pregnancies are less likely to give ... than 37 weeks, gestation -- is the leading ... but its causes remain largely unknown, said Rohini Hernandez, ...
... 30 August 2010 The coming weeks mark the return ... satisfaction of making new friends and obtaining good test scores ... some school-aged adolescents. The previous decade has witnessed a two-fold ... 12 to 17. 1,2 In an effort ...
... often take communication courses unrelated to their major or ... up with the Library and English Departments to develop ... understand literature searchers and incorporate them into papers and ... Gail R. Nonnecke, Iowa State University faculty from the ...
Cached Biology News:BUSPH study observes link between decongestant use in pregnant women and lower risk of preterm birth 2School-based intervention successfully lowers drinking rates in at risk children 2Teaching communication and information literacy skills 2
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Request Info...
...
Highly efficient electroporation solution suitable for transfection of plasmid DNA, oligonucleotides and siRNA. Compatible with all common electroporators....
Biology Products: